$8.95
1.00% today
NYSE, Apr 01, 06:45 pm CET
ISIN
US29384C1080
Symbol
TRDA
Sector
Industry

Entrada Therapeutics Stock price

$9.04
-2.90 24.29% 1M
-6.94 43.43% 6M
-8.25 47.72% YTD
-4.72 34.30% 1Y
-0.35 3.73% 3Y
-14.91 62.25% 5Y
-14.91 62.25% 10Y
NYSE, Closing price Mon, Mar 31 2025
-0.52 5.44%
ISIN
US29384C1080
Symbol
TRDA
Sector
Industry

Key metrics

Market capitalization $339.86m
Enterprise Value $-20.93m
P/E (TTM) P/E ratio 4.74
EV/FCF (TTM) EV/FCF 0.47
EV/Sales (TTM) EV/Sales -0.10
P/S ratio (TTM) P/S ratio 1.61
P/B ratio (TTM) P/B ratio 0.79
Revenue growth (TTM) Revenue growth 63.38%
Revenue (TTM) Revenue $210.78m
EBIT (operating result TTM) EBIT $47.01m
Free Cash Flow (TTM) Free Cash Flow $-44.72m
Cash position $420.00m
EPS (TTM) EPS $1.91
P/E forward negative
P/S forward 8.38
EV/Sales forward negative
Short interest 5.23%
Show more

Is Entrada Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Entrada Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Entrada Therapeutics forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Entrada Therapeutics forecast:

Buy
100%

Financial data from Entrada Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
211 211
63% 63%
100%
- Direct Costs 3.73 3.73
34% 34%
2%
207 207
64% 64%
98%
- Selling and Administrative Expenses 35 35
18% 18%
16%
- Research and Development Expense 122 122
25% 25%
58%
51 51
13,110% 13,110%
24%
- Depreciation and Amortization 3.73 3.73
34% 34%
2%
EBIT (Operating Income) EBIT 47 47
1,587% 1,587%
22%
Net Profit 66 66
1,081% 1,081%
31%

In millions USD.

Don't miss a Thing! We will send you all news about Entrada Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Entrada Therapeutics Stock News

Neutral
GlobeNewsWire
8 days ago
– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing –  – ELEVATE-45 is the second of three novel exon skipping Duchenne programs the Company expects to progress into global clinical development in 2025 – BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today annou...
Neutral
GlobeNewsWire
about one month ago
– Received FDA authorization to initiate ELEVATE-44-102 in the U.S. – – Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. – – Submitted regulatory filings to support global clinical studies for ENTR-601-44 in the EU, and ENTR-601-45 in the U.K. and EU – – Cash runway expected into Q2 2027 with $420 million in cash, cash equivalents and marketable securities as of December 31, 2...
Neutral
GlobeNewsWire
about one month ago
– Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-44-201 – – Expands global ELEVATE-44 clinical program to include pediatric, adult, ambulatory a...
More Entrada Therapeutics News

Company Profile

Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.

Head office United States
CEO Dipal Doshi
Employees 183
Founded 2016
Website www.entradatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today